MHIRJ Announces Authorized Service Facility Agreement with Air Nostrum
MHI RJ Aviation Group (MHIRJ) has announced today at the Farnborough Air Show the signing of an agreement with Air Nostrum Engineering and Maintenance (ANEM), appointing them as a MHIRJ Authorized Service Facility (ASF) in Europe. This agreement marks an important step in expanding MHIRJ’s service network internationally, allowing MHIRJ to extend, in collaboration with ANEM, the same levels of service that customers in North America receive through its wholly owned service centers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220720005641/en/
MHIRJ Announces Authorized Service Facility Agreement with Air Nostrum (Photo: Business Wire)
This agreement expands MHIRJ’s existing ASF support structure in Europe, introducing diversity and additional capacity to the existing network. ANEM’s addition will serve to meet the growing demands of the market, offering a wider array of availability and options for the European sector as well as for MHIRJ customers worldwide.
Based in Valencia (Spain), ANEM is part of the group of companies fully owned by the same shareholders of the airline Air Nostrum. ANEM currently serves as MRO and aircraft maintenance services provider for multiple airlines based in Europe, Africa, and Latin America. Air Nostrum has been operating CRJ Series aircraft since the year 1998 and currently operates the largest CRJ Series fleet in Europe, accounting for 37 CRJ Series aircraft. Air Nostrum is a ten-time MHIRJ Customer Reliability Award winner and a multiple time winner of the ERA Airline of the Year. Their vast operational experience will provide a first-rate base to support the CRJ Series fleet in Europe and across the world. Combining the strengths of ANEM and MHIRJ will bring forth our world-class Aftermarket network to the next level, providing our customers the full suite of MRO services.
Hiro Yamamoto, President and CEO of MHIRJ, commented “We are extremely proud to announce this agreement with Air Nostrum which will benefit customers in the European region, allowing them to access strong MRO support close to home. Reliability has always been the CRJ Series fleet’s strong suit; this agreement maintains that reliability and ensures an even stronger commitment to our customers.”
“ANEM brings a versatile set of capabilities that substantially enhances the CRJ Series MRO support for our European and International customers. As the maintenance arm of the largest CRJ Series carrier in Europe; our strategic collaboration with ANEM favorably positions us to collectively grow and expand support outside of North America,” commented Ismail Mokabel, Senior Vice-President and Head of Aftermarket at MHIRJ.
Amel Belkhamsa, Head of Aftermarket Commercial Services and Spare Parts Operations at MHIRJ, added “This is the first step in broadening our relationship with Air Nostrum to provide support to MHIRJ’s customers outside of North America. We wanted to find an MRO with a large range of capabilities to open the door to even more potential future collaboration, such as in the areas of material support and field response services, to ensure that all our international customers receive the best support available.”
Miguel Falcon, Vice Chairman of Air Nostrum and ANEM, said: “We are delighted to strengthen our cooperation with MHIRJ via this ASF agreement as its next Authorized MRO. We have 24 years of experience with the CRJ Series and have provided exceptional reliability for our customers, and this is due largely to the great relationship that we have with MHIRJ.”
Fermin Tirado, General Manager of ANEM, commented: “Thanks to the dedication and exceptional skills of our team members at ANEM, we´re quite pleased to sign this ASF agreement with MHIRJ that enhances our long-established partnership, allows us to increase the number of employees in ANEM, and grow our capacity for our airline customers.”
About Air Nostrum Group
Air Nostrum Group comprises different companies related to air transport and mobility including airlines, high speed railway transportation and firefighting, as well as related services companies: maintenance, training, flight support etc. The Group flagship, Air Nostrum Líneas Aereas, based in Spain, operates over 70,000 flights carrying more than 4,7 million passengers each year, being the leading regional aviation company in Spain and one of the largest in Europe. It operates for the Iberia Group under the Iberia Regional Air Nostrum brand, has sales over 500 million euros and employs more than 1,400 people.
About ANEM
ANEM is a PART 145 MRO (ES.145.060) and CAMO (ES.CAMO.059) company that arises from the split of AIR NOSTRUM’s business activities. ANEM performs the whole maintenance of the Air Nostrum’s Group fleets, including Air Nostrum, Hibernian, Melair, Paranair and PLYSA. These fleets are: CRJ200, CRJ900, CRJ1000, ATR72-600, and THRUSH S2R-T660. ANEM has a modern Hangar in Valencia Airport in order to cover all maintenance phases of the Air Nostrum’s Group and other operators’ fleets.
About MHI RJ Aviation Group
MHI RJ Aviation Group (MHIRJ) provides comprehensive critical operational, engineering and customer support solutions including maintenance, refurbishment, technical publications, marketing and sales activities for the global regional aircraft industry. Headquartered in Montréal, Canada, and bolstered by an Aerospace Engineering Centre, MHIRJ’s network of service centers, support offices and parts depots are positioned in important aviation hubs in Canada, the U.S. and Germany. A wholly owned subsidiary of Mitsubishi Heavy Industries, Ltd., MHI RJ Aviation Group includes MHI RJ Aviation ULC (Canada), MHI RJ Aviation Inc. (U.S.A.) and MHI RJ Aviation GmbH (Germany).
WE ARE HIRING. Visit mhirj.com/en/careers to know more.
For more information about MHI RJ Aviation Group, please visit: mhirj.com or follow our insights and stories on wingspan.mhirj.com
About MHI Group
Mitsubishi Heavy Industries (MHI) Group is one of the world’s leading industrial groups, spanning energy, logistics & infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life, and ensure a safer world.
For more information, please visit www.mhi.com or follow our insights and stories on www.spectra.mhi.com
*CRJ, CRJ Series and MHIRJ are trademarks of MHI RJ Aviation ULC or its affiliates.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220720005641/en/
Contact information
PRESS CONTACTS:
Ross Mitchell
Vice President, Business Development, Strategy, Marketing, Communications and Business Operations
MHI RJ Aviation Group
+1-416-276-8348
ross.mitchell@mhirj.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom